Celldex Therapeutics

CLDX · NASDAQ

$30.29+$0.62 (+2.09%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $29.67

Latest news

Press releaseOct 12, 9:10 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NewsSep 22, 2:26 PM ETAvi Kapoor
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
NewsSep 22, 12:25 PM ETVandana Singh
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Press releaseSep 22, 6:58 AM ETGlobe Newswire
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Press releaseAug 24, 8:45 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Press releaseAug 6, 4:01 PM ETGlobe Newswire
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
NewsJul 22, 9:19 AM ETAvi Kapoor
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
NewsJul 22, 7:29 AM ETVandana Singh
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Press releaseJul 21, 4:01 PM ETGlobe Newswire
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Press releaseJul 15, 4:01 PM ETGlobe Newswire
Celldex Announces Planned Transition of Chief Financial Officer
Press releaseJun 14, 10:21 AM ETGlobe Newswire
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Press releaseJun 14, 5:15 AM ETGlobe Newswire
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Press releaseJun 10, 4:01 PM ETGlobe Newswire
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
NewsMay 19, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMay 8, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseMay 7, 4:01 PM ETGlobe Newswire
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Press releaseMar 27, 10:30 AM ETGlobe Newswire
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Press releaseFeb 27, 2:45 PM ETGlobe Newswire
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Press releaseFeb 25, 4:01 PM ETGlobe Newswire
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
NewsDec 15, 8:06 AM ETAvi Kapoor
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseNov 10, 4:01 PM ETGlobe Newswire
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 10, 12:31 PM ETPiero Cingari
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?
NewsOct 13, 4:01 PM ET
Analyst Expectations For Celldex Therapeutics's Future
NewsSep 17, 10:01 AM ET
5 Analysts Assess Celldex Therapeutics: What You Need To Know
NewsAug 20, 10:01 AM ET
What Analysts Are Saying About Celldex Therapeutics Stock
NewsAug 20, 8:27 AM ETAvi Kapoor
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsAug 20, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsAug 19, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 7, 4:01 PM ETGlobe Newswire
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NewsJun 13, 12:58 PM ETAvi Kapoor
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
NewsJun 13, 8:01 AM ET
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics
Press releaseMay 8, 4:01 PM ETGlobe Newswire
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
NewsApr 28, 9:00 AM ET
Analyst Expectations For Celldex Therapeutics's Future
NewsMar 20, 6:00 PM ET
7 Analysts Have This To Say About Celldex Therapeutics
Press releaseMar 1, 12:45 PM ETGlobe Newswire
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
NewsFeb 28, 7:01 AM ET
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
Press releaseFeb 27, 4:01 PM ETGlobe Newswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
NewsJan 29, 2:05 PM ET
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
NewsDec 20, 8:02 AM ET
What Analysts Are Saying About Celldex Therapeutics Stock

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex Announces Planned Transition of Chief Financial Officer

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?

Analyst Expectations For Celldex Therapeutics's Future

5 Analysts Assess Celldex Therapeutics: What You Need To Know

What Analysts Are Saying About Celldex Therapeutics Stock

La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Crude Oil Rises 6%; US Consumer Sentiment Surges In June

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

Analyst Expectations For Celldex Therapeutics's Future

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews

What Analysts Are Saying About Celldex Therapeutics Stock